What is HC Wainwright's Forecast for ZVRA Q2 Earnings?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for Zevra Therapeutics in a report issued on Wednesday, July 2nd. HC Wainwright analyst B. Folkes anticipates that the company will post earnings of ($0.09) per share for the quarter. HC Wainwright has a "Buy" rating and a $26.00 price objective on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Zevra Therapeutics' Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.27) EPS, FY2026 earnings at $0.72 EPS, FY2027 earnings at $1.92 EPS, FY2028 earnings at $3.50 EPS and FY2029 earnings at $3.69 EPS.

A number of other research firms have also issued reports on ZVRA. JMP Securities set a $18.00 target price on Zevra Therapeutics in a report on Wednesday, March 12th. Canaccord Genuity Group upped their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a report on Thursday, March 13th. Guggenheim upped their price objective on Zevra Therapeutics from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, March 13th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, May 14th. Finally, Wall Street Zen upgraded Zevra Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $23.14.

Zevra Therapeutics Trading Up 4.0%

NASDAQ:ZVRA opened at $9.79 on Friday. The firm has a market cap of $535.04 million, a P/E ratio of -5.15 and a beta of 1.97. The company has a current ratio of 3.02, a quick ratio of 2.93 and a debt-to-equity ratio of 1.46. The stock's 50 day simple moving average is $8.57 and its 200-day simple moving average is $8.09. Zevra Therapeutics has a 12-month low of $4.20 and a 12-month high of $10.03.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.15. The business had revenue of $20.40 million for the quarter, compared to analyst estimates of $16.96 million. Zevra Therapeutics had a negative return on equity of 201.05% and a negative net margin of 226.78%. During the same quarter in the previous year, the company posted ($0.40) earnings per share.

Institutional Trading of Zevra Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers increased its position in Zevra Therapeutics by 9.6% during the 1st quarter. Rhumbline Advisers now owns 74,585 shares of the company's stock worth $559,000 after purchasing an additional 6,532 shares in the last quarter. Strs Ohio purchased a new stake in Zevra Therapeutics during the 1st quarter worth about $125,000. Woodline Partners LP increased its position in Zevra Therapeutics by 11.5% during the 1st quarter. Woodline Partners LP now owns 4,615,625 shares of the company's stock worth $34,571,000 after purchasing an additional 476,032 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Zevra Therapeutics by 6.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company's stock worth $238,000 after purchasing an additional 1,812 shares in the last quarter. Finally, Retirement Planning Co of New England Inc. increased its position in Zevra Therapeutics by 6.9% during the 1st quarter. Retirement Planning Co of New England Inc. now owns 550,180 shares of the company's stock worth $4,121,000 after purchasing an additional 35,348 shares in the last quarter. Hedge funds and other institutional investors own 35.03% of the company's stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.